Pulse

Today's top news headlines

Pulse Top Story
Financialcontent·12h ago

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis

Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of oral Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist, EVO756, in adults with moderate-to-severe atopic dermatitis (AD).

Trending Now

Trending

Camden Property Trust Announces Participation in Upcoming Real Estate Conferences and Provides Third Quarter 2026 Operating Update

Camden Property Trust (NYSE:CPT) (the “Company”) announced today that the Company will participate in the Evercore Real Estate Conference on September 10, 2026, the Barclays Global Financial Services Conference on September 14, 2026, and the BofA Securities Global Real Estate Conference on September 15-16, 2026. At the BofA conference, Camden’s Executive Team will host a roundtable discussion on Tuesday, September 15, 2026, at 2:15 PM Eastern Time. The event will be webcast live in a

Financialcontent·12h ago·1m
The Daily Pulse

The 5 stories that shaped the world today — in your inbox by 7am.

No fluff. No clickbait. Just the day's most important news, distilled.

More headlines